LY517717

Anticoagulant drugs comprise a specific subcategory of antithrombotic agents that act to inhibit blood coagulation at various… Expand

After the introduction of warfarin, long-term oral anticoagulation treatment remained unchanged for more than 50 years. Most… Expand

Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a… Expand

Following the clinical approval of novel oral anticoagulants as alternatives to the vitamin K antagonists, many additional novel… Expand

Anticoagulation is recommended for prophylaxis and treatment of venous thromboembolism (VTE) (deep vein thrombosis and pulmonary… Expand

In the last 20 years the advent of new technologies, such as high-throughput screening (HTS) and combinatorial chemistry, has… Expand

Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet inhibitor) and vitamin K… Expand

Anticoagulants are recommended for the prevention and treatment of a wide variety of thromboembolic events. Although existing… Expand

Summary.  Background: LY517717 is an oral direct inhibitor of activated factor X that is currently under clinical development.